Sep 16, 2026 —
Eli Lilly and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicines for diseases of the central and peripheral nervous systems, using non-viral delivery.
QurCan’s platform, called Target-Engineered Responsive Polymer (TERP), is a polymer-lipid nanoparticle (PLNP) system designed to carry genetic payloads without a viral vector. Delivering genetic medicines to the nervous system without a virus is a long-standing challenge, and the agreement gives Lilly access to the approach across several neurology programs.
The collaboration is focused on research and development; the companies did not disclose full financial terms.